Cabozantinib
Small molecule
Evidence outlook
Approved: Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Renal Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 3Prostate Cancer · Phase 3
Also approved (6)
- Cabozantinib to treat: • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors. • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors
- COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
- Differentiated Thyroid Cancer CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
- Neuroendocrine Tumors CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
- Renal Cell Carcinoma (RCC) CABOMETYX (cabozantinib) is indicated for the treatment of advanced RCC: • In treatment-naïve adults with intermediate or poor risk. • In adult patients who have received prior therapy. CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC. Hepatocellular Carcinoma (HCC) CABOMETYX is indicated for the treatment of patients with HCC who have been previously treated with sorafenib. Differentiated Thyroid Carcinoma (DTC) CABOMETYX...
- Cabometyx (Ipsen Pharma): advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid carcinoma and neuroendocrine tumours (EU marketing authorisation EMEA/H/C/004163)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
CELESTIAL NCT01908426 · Hepatocellular Carcinoma This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 707 patients with hepatocellular carcinoma who had received sorafenib, assigning 470 to cabozantinib and 237 to placebo. Overall survival, the primary endpoint, was longer with cabozantinib at the prespecified interim analysis (median 10.2 vs 8.0 months; hazard ratio 0.76, 95% CI 0.63 to 0.92; p=0.0049). The record reported no power calculation or planned enrolment, so adequate power could not be confirmed from the sources checked. Registry: NCT01908426 | 3 | Overall Survival (OS) (Up to 45 months) 2017-10-16 | Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (145)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (47)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Used as active comparator (7)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Appears in other studies (10)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Clear Cell Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cabozantinib: this drug | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Casdatifan | Phase 3 | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 2 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Darlifarnib | Phase 1 | Small molecule | Farnesyltransferase | not yet graded | No reviewed efficacy summary in this indication | |
| HS-IT101 | Phase 1 | Cell therapy | Autologous tumor neoantigens (polyclonal, patient-specific) | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb819 | Phase 1 | Multispecific antibody | ENPP3 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CTX131 | Discontinued | Cell therapy | CD70 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(62 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cabozantinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.